[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@MattyKirsh Matthew Kirshner

Matthew Kirshner posts on X about $lxeo, $lrmr, $225m, $400m the most. They currently have XXXXX followers and X posts still getting attention that total XX engagements in the last XX hours.

Engagements: XX #

• X Month XXXXXX -XXXX%
• X Months XXXXXX -XX%
• X Year XXXXXXX +86%

Mentions: X #

• X Month X +17%
• X Months XX -XX%
• X Year XX +81%

Followers: XXXXX #

• X Month XXXXX +6.80%
• X Months XXXXX +15%
• X Year XXXXX +55%

CreatorRank: undefined #

Social Influence #

---

Social topic influence $lxeo 33.33%, $lrmr 33.33%, $225m 33.33%, $400m 33.33%, market cap 33.33%, q2 XXXXX%

Top accounts mentioned or mentioned by @john_hersc79276 @jfais20

Top Social Posts #

---

Top posts by engagements in the last XX hours

"Interesting comparison between $LXEO and $LRMR valuations going after similar indications in FA and FA cardiomyopathy both with FDA-aligned AA pathways. $LRMR: Q2 '26 BLA aligned with FDA (2027 launch) n=65 patients dosed strong early biomarker and efficacy data w/ safety overhang from anaphylaxis. $225M EV ($400M market cap). One trick pony in FA. $LXEO: 2028 launch potential n=16 patients dosed strong early efficacy data + no worrying safety signals yet (aside from typical AAV concerns but the dose is relatively small). Potentially a smaller patient pool going after only cardiomyopathy"
X Link @MattyKirsh 2025-10-08T02:17Z 1836 followers, 6957 engagements